June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
A retrospective analysis of the natural history and management of serpiginous choroidopathy (SC) in Australia and New Zealand
Author Affiliations & Notes
  • Anthony Hall
    Ophthalmology, Alfred Hospital, Melbourne, Prahran, VIC, Australia
    Faculty of Medicine, Nursing and Health Science, Monash University, Melbourne, VIC, Australia
  • Jason Toniolo
    Ophthalmology, Alfred Hospital, Melbourne, Prahran, VIC, Australia
    Faculty of Medicine, Nursing and Health Science, Monash University, Melbourne, VIC, Australia
  • Jo Sims
    Auckland Eye, Auckland, New Zealand
  • Samantha Fraser-Bell
    Sydney Eye Hospital, Sydney, NSW, Australia
  • Jane Khan
    Ophthalmology, Royal Perth Hospital, Perth, WA, Australia
  • Christine Younan
    Ophthalmology, Westmead Hospital, Sydney, NSW, Australia
  • Brian Kent-Smith
    Ophthalmology, Whangarei Area Hospital, Whangarei, New Zealand
  • Stephanie Young
    Ophthalmology, Repatriation General Hospital, Sydney, NSW, Australia
  • Eldho Paul
    Faculty of Medicine, Nursing and Health Science, Monash University, Melbourne, VIC, Australia
  • Lyndell Lim
    Centre for Eye Research Australia, University of Melbourne, Melbourne, VIC, Australia
  • Footnotes
    Commercial Relationships Anthony Hall, None; Jason Toniolo, None; Jo Sims, None; Samantha Fraser-Bell, None; Jane Khan, None; Christine Younan, None; Brian Kent-Smith, None; Stephanie Young, None; Eldho Paul, None; Lyndell Lim, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 5385. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Anthony Hall, Jason Toniolo, Jo Sims, Samantha Fraser-Bell, Jane Khan, Christine Younan, Brian Kent-Smith, Stephanie Young, Eldho Paul, Lyndell Lim, Australian and New Zealand Ophthalmic Surveillance Unit (ANZOSU); A retrospective analysis of the natural history and management of serpiginous choroidopathy (SC) in Australia and New Zealand. Invest. Ophthalmol. Vis. Sci. 2013;54(15):5385.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose
 

To examine the prevalence of serpiginous choroidopathy (SC) in a predominantly Caucasian community, to examine associations between SC and other systemic diseases, and to determine the effect of immunosuppression on the long-term relapse rate of SC.

 
Methods
 

Retrospective cohort study of SC patients using the Australian and New Zealand Ophthalmic Surveillance Unit. Data collected included patient demographics, clinical features, associated systemic diseases, initial and maintenance treatments administered and dates of relapse. Three maintenance treatment groups were identified: No maintenance treatment, maintenance treatment with prednisolone monotherapy and maintenance treatment with combination prednisolone and immunosuppressant therapy. Negative binomial regression was used to calculate incidence rate ratios for patient relapse depending on which maintenance treatment category the patient fell into at the time of relapse.

 
Results
 

18 patients (9 male, 9 female, mean age 48 yrs at baseline) were identified. One patient was seen only once. For the remaining 17 patients, median follow up was 69 months (5.8 years, range 0.4-29.7 years). The prevalence of SC in Australia and NZ was between 1 in 702,000 and 1 in 1.5 million people. Five cases (28%) had a positive QuantiFERON and 1 of these had pulmonary tuberculosis. A total of 32 relapses were observed (1 per 4.8 patient years of followup); 14 whilst receiving no maintenance treatment, 11 on maintenance prednisolone and 7 on maintenance therapy with combined immunosuppressive therapy. Compared to the no treatment group, the incidence rate ratio for relapse on prednisolone monotherapy and combination therapy were 1.29 and 2.92 respectively (95% CI: 0.40-4.14 and 0.96-8.88).

 
Conclusions
 

SC is uncommon in Australia and New Zealand. Tuberculosis is associated with a significant minority of SC cases in Australian and New Zealand. There is a significant subpopulation of patients with SC who have a benign course. Whilst the confidence intervals indicate that the difference in relapse incidence rate ratios are not significant, these treatment results do not suggest a reduced incidence of relapses for patients receiving combination prednisolone and immunosuppressant therapy.

 
Keywords: 746 uveitis-clinical/animal model • 451 chorioretinitis  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×